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New  molecules  such  as  rituximab  or thrombopoietin  receptor  agonists  (romiplostim  and  eltrombopag)
have  changed  the  management  of immune  thrombocytopenia.  Therefore,  old  drugs  which  are  less  expen-
sive and  with  a well-known  beneﬁt/risk  ratio  are  being  underused.  We  aim  to  deﬁne  the  place  of  dapsone,
danazol,  hydroxychloroquine  and  vinca-alkaloids  at the  era  of  targeted  therapy  in  immune  thrombocy-
topenia.  With  a response  rate  around  30%  to 50%,  dapsone  is an  interesting  second-line  therapy  to  beanazol
ydroxychloroquine
inca-alkaloids
used  just  after  corticosteroids.  Patients  with  positive  antinuclear  antibodies  can  beneﬁt  from  hydrox-
ychloroquine  with  a 50%  response  rate.  Because  of its side  effects,  mostly  virilization,  danazol  will be
preferentially  used  in  the  elderly.  Vinca-alkaloids  could  be  temporarily  used  in  patients  that  do not
respond  to intravenous  immunoglobulins  or to limit  their  use  to avoid  shortage  periods.
©  2015  Société  nationale  française  de médecine  interne  (SNFMI).  Published  by  Elsevier  Masson  SAS.
All rights  reserved.. Introduction
Over the last 10 years, the management of immune thrombocy-
openia (ITP) has changed with an increased use of rituximab (RTX)
1] and thrombopoietin receptor agonists (TPO-RA) [2,3]. These
reatments provide good results but remain expensive (Table 1).
esponse rates following RTX are 60%, 40% and 20% after 1, 2 and
 years of follow-up, respectively [4]. Thus, 20% of treated patients
ould expect to be cured with RTX. Unfortunately, the predictive
actors of response have not yet been clearly determined. It has
een suggested, however, that short disease duration and a previ-
us response to corticosteroids were associated with a long-term
esponse to RTX [5]. Recently, a study that analyzed drug consump-
ions in 3000 ITP patients hospitalized each year in France showed
hat more than 600 were treated with RTX, mostly before splenec-
omy, and that its use was stable during the last 3 years [6]. Two
PO-RA are currently available: romiplostim, used subcutaneously,
nd eltrombopag, given orally. The response rate to TPO-RA is
round 80% to 90% [7,8]. In Europe, their use is restricted to ITP
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248-8663/© 2015 Société nationale française de médecine interne (SNFMI). Published bpatients who  are refractory to splenectomy or in whom surgery
is contraindicated. However, TPO-RA are more and more used in
France in persistent ITP before splenectomy. Indeed, they represent
15% of treatments given during the ﬁrst year following diagnosis
of ITP [9]. Furthermore, this percentage will probably increase fol-
lowing the recent publications reporting prolonged remission after
temporary use of TPO-RA in 10 to 30% of patients [10,11].
This situation is striking given the current economic context,
which imposes a rational use of these expensive drugs. More-
over, even if tolerance to TPO-RA after 5 years of use seems good,
long-term toxicity is still not known. In this context, we  aim to
determine the indication of “old molecules” such as dapsone, dana-
zol, hydroxychloroquine and vinca-alkaloids in ITP management,
as their efﬁcacy and side effects are well-known. Moreover, these
drugs are quite inexpensive, as reported in Table 1. Although no
prospective medical-economic study has been conducted in ITP,
data suggest that using RTX before TPO-RA could be less expensive
in patients refractory to splenectomy [12].
2. ITP: deﬁnitions and current therapeutic strategyDuring the past few years, ITP terminology has been clari-
ﬁed [13]. “Newly diagnosed ITP” is used during the 3 months
following diagnosis; “persistent ITP” deﬁnes the period lasting
between 3 to 12 months after diagnosis, and after 1 year of disease
y Elsevier Masson SAS. All rights reserved.
44 S. Audia et al. / La Revue de médec
Table  1
Cost of the different treatments (molecules only).
Molecule Dosage Monthly cost
(28 days) or one
course treatment
(*)
Danazol 200 mg  twice or three times a
day
D  51 to 76
Dapsone 100 mg/day D 4
Eltrombopag 50 mg/day D 2.225
Hydroxychloroquine 200 mg  twice a day D 10
Intravenous
immunoglobulins
(IVIg)
1  g/kg for 70 kg weight D 2.870*
Rituximab 1 g at day 1 and day 15 D 5.275*
Romiplostim 3 g/kg/week (weight < 85 kg)
250 g vial
D 2.773
3  g/kg/week (weight > 85 kg)
500 g vial
D 5.381
Vinblastine 5 mg/week D 30
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Vincristine 2 mg/week D 58
uration, the term “chronic ITP” is used. “Refractory ITP” character-
zes patients with thrombocytopenia below 20 G/L and/or bleeding
anifestations despite splenectomy [13]. However, this deﬁnition
hould probably be reﬁned and extended to patients that are non-
esponders to splenectomy, RTX and TPO-RA in succession [14].
Current ITP management [15] could be summarized as follows:
corticosteroids are the ﬁrst-line therapy, also used as a diag-
nostic test, with a response rate around 70% to 80%. Usually,
a short treatment duration (3 to 4 weeks) with prednis(ol)one
(1 mg/kg/d) is recommended [15]. Dexamethasone, 40 mg/d dur-
ing 4 consecutive days, also provides good results [16];
intravenous immunoglobulins (IVIg) should only be used in
emergency situations associated with corticosteroids. IVIg are
indicated depending on the bleeding score rather than platelet
count [17];
splenectomy is the second-line therapy proposed after 1-year of
evolution;
TPO-RA are used to treat patients who are refractory to splenec-
tomy.
However, the therapeutic strategy during the ﬁrst year following
iagnosis is still not clearly deﬁned, particularly in patients who
elapse after steroids, which is a frequent situation. RTX and TPO-
A are more and more used off-label during this phase [9], although
ld molecules such as dapsone, danazol, hydroxychloroquine and
inca-alkaloids could be useful at this stage.
. What place remains for the “old therapies”?
.1. Dapsone
The ﬁrst use of dapsone during ITP was reported in the 1990’s by
urand et al. [18], and its efﬁcacy was further conﬁrmed in larger
eries (Table 2) [19–27].
The mechanisms of action of dapsone are not well-known. One
ypothesis is that the hemolysis induced by the drug (there is usu-
lly a decrease of 1–2 g/dL in the hemoglobin level) could limit the
hagocytosis of opsonized platelets by splenic macrophages [18].
here is indirect evidence supporting this hypothesis, for exam-
le, a greater degree of hemolysis in responder patients and a
ower response rate in splenectomized patients [21]. Dapsone is
lso known to decrease the cytotoxic functions of neutrophils [28],
 mechanism that is probably not preponderant during ITP.ine interne 37 (2016) 43–49
The response rate to dapsone is around 30% to 50%, and is only
suspensive in most cases [18,19,21]. Once the response is obtained,
the drug can be tapered progressively. In rare cases, the response
persists after dapsone discontinuation [21,23,25,26]. In cases of
relapse, a new response could be achieved by resuming the drug,
but sometimes after a long interval [29]. No individual predictive
response factors have been identiﬁed. In particular, the acetylation
proﬁle does not correlate with response rate, even though dap-
sone is metabolized by N-acetyltransferase [22]. Dapsone can be
used after splenectomy, but the response rate is usually half that in
non-splenectomized patients [19–21,23]. Dapsone is also effective
in secondary ITP, notably due to HIV infection [19,24], in which
it will also provide a prophylactic effect against pneumocystosis.
Overall, tolerance to dapsone is good, with a discontinuation rate
due to side effects of 4 to 24%. It is worth noting that in all studies,
patients with glucose-6-phosphate-deshydrogenase (G6PD) deﬁ-
ciency were excluded because of the increased risk of hemolysis.
Cutaneous hypersensitivity is a frequent side effect that occurs in
7% of patients [30]. It consists of a rash with pruritus associated with
systemic symptoms in the most severe cases, leading to the diagno-
sis of drug rash with eosinophilia and systemic symptoms (DRESS).
Usually, the rash occurs within the ﬁrst 4 weeks of treatment. Both
patients and referent general practitioners must be aware of this
potential harmful side effect; discontinuation of the drug is manda-
tory as soon as these symptoms appear [31].
Proposition: dapsone is a suspensive therapy with a good ben-
eﬁt/risk ratio. The drug constitutes an interesting second-line
therapy, particularly in persistent ITP, as recommended [15,32].
A national randomized prospective study (DAPS-ITP study) con-
ducted in France by the French reference center for autoimmune
cytopenias will probably conﬁrm the results obtained in retrospec-
tive studies. Strong adherence to treatment and good knowledge
of the potential side effects (most particularly cutaneous hyper-
sensitivity) are needed. Screening for G6PD X-linked deﬁciency
is important in men, as soon as the diagnosis of ITP is made,
in order to start the drug rapidly in case of relapse following
steroid discontinuation. As the median response time is 3–4 weeks,
concomitant treatment with corticosteroids is usually required.
Moreover, it seems that this co-prescription decreases the risk of
harmful side effects [30]. Once a stable response is obtained, the
drug can be tapered very progressively. We  recommend measur-
ing methaemoglobinaemia only in cases of suggestive symptoms
such as cyanosis or dyspnea; a blood level below 7% is required
for treatment continuation. A full blood count is also needed
during follow-up because of the hemolysis induced by dapsone,
and agranulocytosis also needs to be checked for. Both hemolysis
and methaemoglobinaemia are dose-dependent, thus a decrease
in dapsone dosage could be sufﬁcient to reverse these side
effects. Interestingly, dapsone can be maintained during pregnancy
[33]. Hemolysis and moderate methaemoglobinaemia have been
reported in new-borns whose mothers were treated with dap-
sone during pregnancy. In such cases, these side effects must be
checked at birth [34]. Because of the high concentration of the drug
in maternal milk, breastfeeding is strongly discouraged (Centre de
Référence sur les Agents Pathogènes, French reference center on
pathogenic drugs, http://www.lecrat.org). It should be known that
as dapsone pills contain iron, they induce black coloration of the
feces that should not be misdiagnosed as melena in this context
of thrombocytopenia. Moreover, as eltrombopag absorption could
be disturbed by concomitant divalent ion intake, the utilization of
both molecules simultaneously should be avoided.3.2. Danazol
Danazol displays multiple immunomodulatory mechanisms. It
induces a decrease in Fc receptor expression on monocytes [35]
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Table 2
Dapsone in immune thrombocytopenia.
Study Godeau et al.,
1993 [19]
Hernandez
et al., 1995
[20]
Godeau et al.,
1997 [21]
Le Louet et al.,
1999 [22]
Damodar et al.,
2005 [23]
Vancine-
Califani et al.,
2008 [24]
Audia et al.,
2010 [25]
Zaja et al.,
2012 [26]
Patel and Patil,
2015 [27]
Number of patients 21 15 66 19 90 40 19 20 38
Mean  age, years 45 54.5 45.5 48 Adults: 28.8
Children: 8.1
34.7 48.6 51 Adults: 39.5
Children: 7.9
Study  design Prospective Prospective Prospective Prospective Retrospective Retrospective Retrospective Prospective Retrospective
Dapsone  dosage 100 mg/d 100 mg/d 75–100 mg/d 100 mg/d 1–2 mg/kg/d 100 mg/d 100 mg/d 50 then
100 mg/d
1.6 mg/kg/d
Persistent/chronic ITP 20 (95%) 15 (100%) 66 (100%) 19 (100%) 90 (100%) ND 11 (58%) ND 37 (97.3)
Median  duration of ITP,
months (range)
13
(2–240)
29
(12–131)
52
(3–240)
ND 24.5 (6–132)
Adults: 26.8
(6–120)
Children: 21.8
(6–132)
5
(1–29.9)
40
(0.2–249)
46
(2–274)
ND
Response rate, % (n) 47.6%
(10/21)
40%
(6/15)
50%
(33/66)
47.3%
(9/19)
Adults: 61.8%
Children: 65.7%
50%
(20/20)
42.1%
(8/19)
55%
(11/20)
Adults: 45.5%
Children: 55.5%
Median  time to response,
days (range)
30
(12–120)
30 21
(8–90)
ND 105
(30–270)
ND 42
(15–90)
30
(15–60)
57
(19–108)
Predictive response factors Platelet count
R/NR
(28 vs. 10 G/L)
None Platelet count
R/NR
(28 vs. 18 G/L)
ND Platelet count
CR/NR
(18 vs. 10 G/L)
None ND None None
Relapse  during treatment, %
(n)
ND ND 5%
(1/20)
ND ND 5% 0 0 11.1%
(2/18)
Treatment discontinuation
due to side effects, % (n)
24%
(5/21)
20%
(3/15)
10.6%
(7/66)
ND 3%
(3/90)
5.8%
(3/52)
10.5%
(2/19)
0%
(0/20)
5.2%
(2/38)
Splenectomy, n 3/21 4/15 12/66 ND 11/90 Excluded 1/19 5/20 1/38
Response  rate in
splenectomized patients,
% (n)
33%
(1/3)(+danatrol)
50%
(2/4)
25%
(3/12)
ND 27.3%
(3/11)
– 0
(0/1)
ND 0
(0/1)
ITP: immune thrombocytopenia; ND: non-determined; NR: non-responders; R: responders.
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hat could lead to a decrease in platelet phagocytosis. Danazol also
educes the proliferation of lymphocytes upon stimulation with
itogens [36]. More recently, it has been shown in mice that dana-
ol diminishes the production of pro-inﬂammatory cytokines, such
s IL-2 and IFN- while increasing anti-inﬂammatory cytokines like
L-10. Moreover, danazol promotes lymphocyte differentiation into
egulatory T lymphocytes [37].
Used at 200 mg,  3 times a day in ITP, response rates ranged
rom 40% to 70% [38–45]. Once the response is obtained, danazol
an be progressively tapered to 200 mg  per day [44] and even as
ow as 50 mg  per day [40], which improves tolerance to the treat-
ent. Withdrawal of the treatment due to side effects is reported
n 6% to 16% of patients. Cytolysis (2 to 10 times the normal range)
s observed in 50% to 85% patients [45,46]. More harmful side
ffects such as peliosis [47], liver cancer [48], thrombosis [49] or
ulmonary ﬁbrosis [50] have been reported. Usually, the time to
chieve a response is long, around 2 to 3 months: only 7% of patients
espond after 1 month up, rising to 60% after 6 months [45]. A
elapse can occur during treatment in 20% to 70% of patients.
Until now, the most informative study was conducted by Mal-
isel et al. [44]. Fifty-seven patients, mean age of 54 years, were
reated with danazol 200 mg  3 times a day with progressive taper-
ng once a response was achieved. The overall response rate was
7%, with a 10-year response rate of 42%. A relapse occurred in
2% of patients during the treatment. The median time to response
as as long as 3 months. Side effects requiring drug discontinua-
ion, mostly liver cytolysis, occurred in 16%. Patients over 45 years
eem to have a better response than younger patients (47% vs.
5%). No predictive response factors have been identiﬁed. In par-
icular, splenectomy does not change the response rate (63% in
plenectomized ITP patients vs. 70% in chronic unsplenectomized
TP patients).
Danazol is also effective to treat thrombocytopenia during
yelodysplastic syndromes (MDS) [51–53], which represent the
ajor differential diagnosis of ITP, notably in the elderly. Thus,
hen the diagnosis is not clearly established between ITP and MDS
espite bone marrow explorations, danazol could be an interesting
herapy.
Proposition: danazol is a less expensive alternative to TPO-RA
nd could be proposed to patients older than 65 years who  have
 contraindication for splenectomy or those with refractory ITP.
owever, a concomitant treatment is needed particularly if the
atient presents bleeding symptoms or if the platelet count is
elow 20 G/L because this drug takes at least 2 months to induce
 response. Therefore, danazol cannot be used as a rescue therapy.
oreover, liver enzymes should be checked regularly to screen for
ytolysis, which is the most frequent side effect leading to drug dis-
ontinuation. Because of its androgenic properties, danazol triggers
irilization and is contraindicated during hormonodependent can-
ers. We  thus recommend systematic measuring prostate speciﬁc
ntigen (PSA) before starting the drug, and referring men  older than
0 years to an urologist. A previous history of thrombosis is also a
ontraindication to danazol. Because of its low beneﬁt/risk ratio,
he use of danazol should therefore be restricted to the elderly and
en  who do not suffer from prostate cancer.
.3. Hydroxychloroquine
Hydroxychloroquine (HCQ) acts via multiple mechanisms
54]: alteration of lysosome acidiﬁcation, decrease in both T
nd B cell activation by blocking calcium-dependent recep-
ors, anti-inﬂammatory effects by decreasing prostaglandin
roduction through phospholipase A2 inhibition, decrease in pro-
nﬂammatory immune response by dampening cytokine secretion
nd antigen presentation by monocytes and macrophages, decrease
n danger signal receptor signaling (toll-like receptor 7 and 9ine interne 37 (2016) 43–49
notably), DNA stabilization and protection against ultraviolet radi-
ation, and inhibition of autophagy [55].
The efﬁcacy of HCQ was ﬁrst demonstrated in ITP secondary to
lupus [56]. HCQ allowed a decrease in exposure to corticosteroids
and led to a 50% response in association with corticosteroids.
More recently, the usefulness of HCQ has been reported in pri-
mary ITP with biological markers of lupus [57]. Forty patients, mean
age of 35 years, suffering from ITP with positive antinuclear anti-
bodies (ANA, level > 1/160, median level: 1/1280), among whom
30% were affected by lupus according to the American College of
Rheumatology criteria, were treated with HCQ 200 mg twice a day
(83%). During the ﬁrst 2 months, the response rate was 27%, and
rose to 60% after a mean delay of 3 months (range: 2–6 months).
No relapse was observed during treatment. Although the response
rate was lower than in lupus patients (83%), half of the primary
ITP patients with positive ANA achieved a response. No side effects
were observed during this study. In our experience, primary ITP
patients who  do not have biological markers of lupus have a lower
response rate (unpublished data).
Proposition: HCQ could be used in primary ITP with positive ANA
(level > 1/160). Because of its long response time (6 to 12 weeks), a
concomitant treatment, mostly corticosteroids, should be used for
the ﬁrst months of treatment, particularly when the platelet count
is below 20 G/L or when bleeding symptoms are observed. Impor-
tantly, the response could not be determined before 3 months of
treatment, as a delayed response can be observed. During lupus,
HCQ usually corrects the thrombocytopenia (83%). Importantly,
HCQ can be maintained during pregnancy and breastfeeding.
3.4. Vinca-alkaloids: vincristine, vinblastine
Vinca-alkaloids were ﬁrst used in ITP in the 1970’s [58–60].
Vinblastine-loaded platelets were ﬁrst used to target macrophages
and inhibit their phagocytic functions [61]. It was then demon-
strated that vinca-alkaloids could be advantageously used as a
intravenous bolus with similar efﬁcacy [62].
Studies that included more than 10 patients are reported in
Table 3 [62–66]. The efﬁcacy of vinca-alkaloids seems to be higher
in newly diagnosed ITP than in persistent and chronic ITP. A lower
response in splenectomized patients is also reported. However,
refractory ITP patients could beneﬁt from vinca-alkaloids [67]. Usu-
ally, vincristine is used at a dosage of 1 mg/week, no longer than
4 weeks [65]. Vinca alkaloid effect is only suspensive with a sus-
tained response of 37% and 20% at 1 and 2 years, respectively [65].
Thus, they represent an interesting rescue therapy but cannot be
used as a long-term therapy because of their toxicity, particularly
peripheral neuropathy.
The usefulness of vinca-alkaloids to increase platelet count
before splenectomy was  investigated [66]. Twelve patients were
treated with vinca-alkaloids (weekly perfusion of 2 mg  of vin-
cristine or 10 mg  of vinblastine). The platelet count rose to above
80 G/L in 75%, and non-responders were effectively treated with
IVIg to allow surgery. Complications due to vinca-alkaloids were
mostly neuropathy (peripheral in 3 cases, autonomic neurop-
athy triggering constipation in 2 cases). The use of vinca-alkaloids
was 30 times less expensive than IVIg, though IVIg were used at
400 mg/kg/d for 5 days, an infusion protocol that is rarely used
nowadays. This efﬁcacy of vinca-alkaloids has been conﬁrmed in
animal models [68]. Vinca-alkaloids are contraindicated during
pregnancy and breastfeeding. Vinblastine can be used in children
with a response rate of 47% to 64% [69].
Proposition: patients who are resistant to IVIg could beneﬁt
from vinca-alkaloids with a mean time to response of 10 to 20 days.
Because of their suspensive effect, long-term use is not recom-
mended, and in persistent/chronic ITP, another treatment should
be considered. During IVIg shortage, vinca-alkaloids represent an
S. Audia et al. / La Revue de médecine interne 37 (2016) 43–49 47
Table  3
Vinca-alkaloids and immune thrombocytopenia.
Study Fenaux et al., 1990 [42] Facon et al., 1994 [62] Sikorska et al.,
2004 [64]
Szczepanik et al., 2007
[66]
Stirnemann et al.,
2015 [65]
Patients, n 43 42 22 12 35
Mean  age, years (range) 56 (18–91) 54 (12–84) 56 (17–77) 46.8 (1–66) 58 (16–93)
Study design Prospective Prospective Retrospective Prospective:
preparation for
splenectomy
Retrospective
Dosage  0.1 mg/kg, 6 hour
infusion/week
0.1 mg/kg, 6 hour
infusion vs.
bolus/week
Vincristine:
2 mg/week
Vinblastine:
10 mg/week
Vincristine: mg/week
Vinblastine:
10 mg/week
Vincristine
Bolus
(1–1.5 mg/week)
Persistent/chronic ITP < 6 months: 19
>  6 months: 24
< 6 months: 25
> 6 months: 17
< 6 months: 2
> 6 months: 20
100% 83% (29)
Response rate, % (n)
> 30 G/L and at least twice
baseline level
65.1%
(27/43)
76% (16/21): 6 hours
67% (14/21): bolus
41%
(9/22)
75%
(9/12)
86%
(30/35)
Median time to response, days 18.5 days (response
rate determined after
6 weeks)
10 days (response rate
determined after
6  weeks)
Response rate
determined after
4 weeks
Response rate
determined after
4 weeks
7 days
Predictive response factors “Acute” ITP ND “Acute” ITP,
antiplatelet
antibodies
ND “Acute” ITP
Side  effects 25.5% [leukopenia (9),
neutropenia (1),
neuropathy (2)]
21.5% (9/42)
Neuropathy (6),
neutropenia (3), rash
(2)
23% (5/22)
Neuropathy
Neuropathy (3),
constipation (2)
23% (8/35)
Neuropathy (7),
intestinal ileus (1)
Splenectomy 17/43 8/17 3/22 – 6/35
Response in splenectomized
patients
47% vs. 80%
ITP > 6 months
non-splenectomized
patients
50% vs. 77%
ITP > 6 months
non-splenectomized
patients
100% – ND
ITP: immune thrombocytopenia; ND: non-determined.
Table 4
Treatment propositions.
Drugs Indications
Dapsone 2nd line therapy after corticosteroids
Rule out G6PD deﬁciency particularly in men
Non-splenectomized patients (less effective after
splenectomy)
Not contraindicated during pregnancy
Danazol Patients > 65 years
Non-splenectomized or splenectomized patients
When thrombocytopenia due to myelodysplastic
syndrome is not completely excluded
Hydroxychloroquine ITP secondary to lupus
Primary ITP with antinuclear antibodies (> 1/160)
Not contraindicated during pregnancy and
breastfeeding
Vinca-alkaloids Non-responders to IVIg and corticosteroids
To increase platelet count before splenectomy
G
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o6PD: glucose-6-phosphate-deshydrogenase; ITP: immune thrombocytopenia;
VIg: intravenous immunoglobulins.
nteresting alternative to prepare patients for splenectomy when
teroids are ineffective: started 3 weeks before surgery, an increase
n platelet count will be achieved in 75%. Usually, vinblastine is pre-
erred to vincristine because of its better tolerance. There is indeed a
isk of peripheral neuropathy, particularly in the elderly, that could
ead to intestinal occlusion, particularly with vincristine. The drug
hould be administered intravenously and slowly as extravasation
ould lead to extensive cutaneous necrosis. Vinblastine is used at
 mg/m2 (no more than 7 mg  total dose/injection), which can be
epeated once or twice every 10 days.
. ConclusionsThe use of new treatments such as RTX and TPO-RA in ITP has
ed to a major improvement in patient management. However,
ld molecules should not be forgotten and are still useful inspeciﬁc conditions (Table 4), particularly because their efﬁcacy
and tolerance are well-known, and also because of their low cost.
We thus suggest using dapsone as soon as possible in evolving
ITP because of its safety and efﬁcacy, which is assessed after
3–6 weeks. The prospective study being conducted in France
will describe the efﬁcacy of and tolerance to the molecule more
precisely. When ineffective, and in ITP patients with positive ANA
(> 1/160), hydroxychloroquine is an interesting alternative with
a good response rate, which is often delayed (3 months), in half
of the cases. Due to its virilizing effects and the potential risk of
liver cancer, danazol will be used in elderly patients (> 65 years)
only after ruling out prostate cancer or a previous history of
thrombosis, and with a careful surveillance of liver enzymes. As
the time to a response with hydroxychloroquine and danazol is
long (around 2–3 months), a concomitant treatment should be
transiently used particularly in patients with bleeding events or
when the platelet count is below 20 G/L. Vinca-alkaloids can be
used in patients who do not respond to IVIg or as an alternative
treatment to IVIG before surgery, notably splenectomy. Vinblastine
will be used preferentially because of its lower risk of neuropathy
compared with vincristine, particularly in the elderly. However,
the prolonged use of vinca-alkaloids is not recommended.
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